Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · IEX Real-Time Price · USD
3.450
-0.020 (-0.58%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Trevi Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Selling, General & Admin
10.2410.079.4910.167.314.342.14
Research & Development
23.6819.8322.9822.3319.3414.076.1
Operating Expenses
33.9229.9132.4832.4926.6518.418.24
Operating Income
-33.92-29.91-32.48-32.49-26.65-18.41-8.24
Interest Expense / Income
0.391.161.20.4600.173.34
Other Expense / Income
-5.22-1.880.28-0.17-0.582.091.31
Pretax Income
-29.1-29.19-33.96-32.78-26.07-20.67-12.89
Income Tax
-0.03-0.04-0.02-0.02-0.02-0.12-0.03
Net Income
-29.07-29.15-33.94-32.76-26.05-20.55-12.86
Preferred Dividends
00000.75.03-0.32
Net Income Common
-29.07-29.15-33.94-32.76-26.75-25.58-12.54
Shares Outstanding (Basic)
996523181200
Shares Outstanding (Diluted)
996523181200
Shares Change
53.44%182.56%26.48%53.88%2581.79%4.02%-
EPS (Basic)
-0.29-0.45-1.49-1.81-2.28-58.44-29.80
EPS (Diluted)
-0.29-0.45-1.49-1.81-2.28-58.44-29.80
Free Cash Flow
-31.85-28.33-28.95-29.03-23.1-18.45-7.99
Free Cash Flow Per Share
-0.32-0.44-1.27-1.61-1.97-42.15-18.99
EBITDA
-28.58-27.98-32.71-32.27-26.03-20.47-9.54
Depreciation & Amortization
0.120.040.050.050.040.020
EBIT
-28.71-28.03-32.76-32.32-26.07-20.5-9.54
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).